Toll-like Receptors

Kdo2-Lipid A ammonium is a selective TLR4 activator known for its potent endotoxin activity comparable to that of lipopolysaccharide (LPS). It effectively stimulates the release of pro-inflammatory mediators, including tumor necrosis factor (TNF) and prostaglandin E2 (PGE2). This compound is widely utilized in immunological research to investigate TLR4 signaling pathways and the associated inflammatory responses.

Diprovocim is a potent TLR1/TLR2 agonist that activates immune responses by inducing full agonist activity in human THP-1 cells, with an EC50 of 110 pM. This compound effectively stimulates TNF-α release from mouse macrophages at an EC50 of 1.3 nM. By activating downstream signaling pathways, including MAPK and NF-κB, Diprovocim demonstrates significant adjuvant activity in mice, enhancing cellular immune responses and making it a valuable tool for immunological research.

MC-Val-Cit-PAB-Amide-TLR7 Agonist 4 is a HER2-targeted TLR7 and TLR8 immune agonist conjugate. This compound activates Toll-like receptors, enhancing immune responses through the stimulation of both innate and adaptive immunity. It is primarily utilized in research applications aimed at cancer immunotherapy, particularly in enhancing the immune system's ability to target HER2-expressing tumors.

TLR7 Agonist 12 is a potent TLR7 agonist and a purine nucleoside analog. This compound demonstrates significant antitumor activity, particularly against indolent lymphoid malignancies. Its anticancer mechanisms are mediated through the inhibition of DNA synthesis and the induction of apoptosis, making it valuable for research applications in cancer therapeutics and immune modulation studies.

TLR8 Agonist 4 is a potent agonist targeting Toll-like receptor 8 (TLR8), demonstrating efficacy against both wild-type and drug-resistant HBV strains, including those resistant to lamivudine and entecavir. The compound exhibits IC50 values of 0.15 μM and 0.10 μM, respectively, highlighting its potential for use in antiviral research and therapeutic development against Hepatitis B virus.

SMU-L11 is a selective TLR7 agonist with an EC50 of 0.024 μM, which engages the MyD88 adapter protein to activate downstream NF-κB and MAPK signaling pathways. This compound significantly enhances immune cell activation in murine models, promoting the proliferation of CD4+ T and CD8+ T cells, leading to direct tumor cell lysis and inhibition of tumor growth. SMU-L11 is a valuable reagent for cancer research and can also be utilized for investigations into immune system-related diseases.

HCN-IN-1 is a TLR4 inhibitor and modulator of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, specifically targeting HCN2 and HCN4. It effectively inhibits TLR4-mediated signaling, evidenced by reduced alkaline phosphatase activity. HCN-IN-1 modulates HCN2 currents by shifting the voltage-dependent activation to hyperpolarized potentials and slowing activation kinetics, while also blocking currents through HCN4 channels. This compound demonstrates significant analgesic, anti-inflammatory, and anti-anginal properties, making it valuable for research into inflammatory pain, neuropathic pain, heart failure, and related inflammatory conditions.

Xelafaslatide is a Fas receptor antagonist that effectively inhibits Fas receptor signaling, thereby blocking downstream apoptosis and inflammatory pathways. This compound demonstrates significant potential in suppressing neuroinflammation and microglial activation in glaucoma models, offering protection to retinal ganglion cells and preventing axonal degeneration. Xelafaslatide is relevant for research focused on glaucoma and related neurodegenerative conditions.